Table 3.
Assessment of CSPG effects on microglia experimental groups
| Experimental group | Treatment | Cell plating (3 h post treatment) |
|---|---|---|
| M0 (no treatment) | – | 1) PDL 2) PDL + CSPGs (5 μg/ml) 3) PDL + CSPGs (5 μg/ml) + ChABC (0.1 U/ml) |
| ILP (10 μM) + ISP (10 μM) | 1) PDL 2) PDL + CSPGs (5 μg/ml) |
|
| Y-27632 (ROCK inhibitor, 10 μM) | 1) PDL 2) PDL + CSPGs (5 μg/ml) |
|
| TAT (20 μM) | 1) PDL 2) PDL + CSPGs (5 μg/ml) |
|
| IMP (10 μM) | 1) PDL 2) PDL + CSPGs (5 μg/ml) |
|
| M1 (40 ng/ml TNFα + 50 ng/ml IFNγ) | – | 1) PDL 2) PDL + CSPGs (5 μg/ml) 3) PDL + CSPGs (5 μg/ml) + ChABC (0.1 U/ml) |
| ILP (10 μM) + ISP (10 μM) | 1) PDL 2) PDL + CSPGs (5 μg/ml) |
|
| Y-27632 (ROCK inhibitor, 10 μM) | 1) PDL 2) PDL + CSPGs (5 μg/ml) |
|
| TAT (20 μM) | 1) PDL 2) PDL + CSPGs (5 μg/ml) |
|
| IMP (10 μM) | 1) PDL 2) PDL + CSPGs (5 μg/ml) |
|
| M2 (10 ng/ml IL10) | – | 1) PDL 2) PDL + CSPGs (5 μg/ml) 3) PDL + CSPGs (5 μg/ml) + ChABC (0.1 U/ml) |
| ILP (10 μM) + ISP (10 μM) | 1) PDL 2) PDL + CSPGs (5 μg/ml) |
|
| Y-27632 (ROCK inhibitor, 10 μM) | 1) PDL 2) PDL + CSPGs (5 μg/ml) |
|
| TAT (20 μM) | 1) PDL 2) PDL + CSPGs (5 μg/ml) |
|
| IMP (10 μM) | 1) PDL 2) PDL + CSPGs (5 μg/ml) |